Aggarwal, Rahul

Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study

Aggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., et al. (2018) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchNeuroblastoma Research and Treatments

Cited by 810

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., et al. (2018) · Cell

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 733

Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial

Aggarwal, R., Starzinski, S., de Kouchkovsky, I., Koshkin, V., Bose, R., Chou, J., Desai, A., Kwon, D., Kaushal, S., Trihy, L., et al. (2023) · The Lancet Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 104

Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer

Su, Y., Liu, Y., Behrens, C. R., Bidlingmaier, S., Lee, N.-K., Aggarwal, R., Sherbenou, D. W., Burlingame, A. L., Hann, B. C., Simko, J. P., et al. (2018) · JCI Insight

Prostate Cancer Treatment and ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 82

A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors

Mansfield, A. S., Hong, D. S., Hann, C. L., Farago, A. F., Beltran, H., Waqar, S. N., Hendifar, A. E., Anthony, L. B., Taylor, M. H., Bryce, A. H., et al. (2021) · npj Precision Oncology

Neuroendocrine Tumor Research AdvancesMonoclonal and Polyclonal Antibodies Research

Cited by 80

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer

Lim, E. A., Schweizer, M. T., Chi, K. N., Aggarwal, R., Agarwal, N., Gulley, J., Attiyeh, E., Greger, J., Wu, S., Jaiprasart, P., et al. (2023) · Clinical Genitourinary Cancer

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 62

Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).

Beltran, H., Dowlati, A., Jain, P., Johnson, M. L., Sanborn, R. E., Thompson, J. R., Mamdani, H., Schenk, E. L., Aggarwal, R. R., Sankar, K., et al. (2024) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 32

Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC).

Aggarwal, R. R., Rottey, S., Bernard-Tessier, A., Mellado-Gonzalez, B., Kosaka, T., Stadler, W. M., Sandhu, S., Yu, B., Shaw, C., Ju, C.-H., et al. (2024) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 29

1804P APEX-01: First-in-human phase I/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Shen, J., Pachynski, R., Nordquist, L. T., Adra, N., Bilen, M. A., Aggarwal, R., Reichert, Z., Schweizer, M., Iravani, A., Aung, S., et al. (2023) · Annals of Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 24

Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC).

Aggarwal, R. R., Vuky, J., VanderWeele, D. J., Rettig, M., Heath, E. I., Beer, T. M., Huang, J., Pawlowska, N., Sinit, R., Abbey, J., et al. (2022) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 22

The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer

Lin, C., Hadfield, M. J., Santopietro, A., Lagos, G., Cheng, L., El-Deiry, W. S., Aggarwal, R., Mega, A., Hyams, E., & Carneiro, B. A. (2025) · npj Precision Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 20

A phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC).

Shakhnazaryan, N., Curry, N., Rastogi, M., Avins, D., Pandey, S., de Kouchkovsky, I., Kwon, D., Desai, A., Fitzgerald, K. N., Bose, R., et al. (2024) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 6

591P A first-in-human study of FOR46 in men with metastatic castration resistant prostate cancer (mCRPC)

Aggarwal, R. R., Vuky, J., VanderWeele, D., Rettig, M., Heath, E., Nasoff, M., Dorr, A., Liu, B., & Small, E. J. (2021) · Annals of Oncology

Prostate Cancer Treatment and ResearchProtein Degradation and Inhibitors

Cited by 1